An eight-week, randomized, controlled study published today in AJP in Advance has found that a 1.5 m...
In July, lurasidone—a dopamine receptor 2 (D2) blocker originally approved to treat schizophrenia—wa...
The U.S. Food and Drug Administration (FDA) has approved new indications for the atypical antipsycho...
